A Closer Look at 21 Analyst Recommendations For Biogen
Portfolio Pulse from Benzinga Insights
21 analysts provided mixed ratings for Biogen (NASDAQ:BIIB) with a downward trend in the 12-month price target, now averaging $299.05, 5.62% lower than the previous $316.85. The analysis reflects adjustments in ratings and price targets by key analysts due to changing market conditions and Biogen's performance. Despite the diverse ratings, the company faces challenges in financial performance, with a -6.2% revenue decline, below industry benchmarks in net margin, ROE, and ROA, and a prudent debt management strategy.
March 05, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen received mixed analyst ratings with a downward revision in the 12-month price target. Financial challenges include a -6.2% revenue decline and below-average performance in net margin, ROE, and ROA.
The mixed analyst ratings combined with a downward revision in price targets suggest caution among analysts regarding Biogen's future stock performance. The financial challenges highlighted, including a significant revenue decline and below-average performance metrics, further contribute to a negative outlook for the stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100